Emphasizing the benefits of annual lung cancer screening with low-dose computed tomography (CT), researchers noted high 20-year survival rates for a variety of early-stage lung cancer tumor presentations, including a 100 percent survival rate for those with non-solid or partly solid cancerous nodules.
A recent report from the American Lung Association indicated that only 5.8 percent of Americans eligible for lung cancer screening follow through with the preventative, life-saving measure.1
However, detection of early-stage lung cancer via low-dose computed tomography (CT) may lead to a 20-year survival rate of 80 percent, according to the findings of a large international study being presented next week at the Radiological Society of North America (RSNA) annual conference in Chicago.2
In the study of 1,285 people with early-stage lung cancer diagnosed on CT scans, researchers noted a 100 percent 20-year survival rate for 139 study participants with non-solid lung nodules, and 155 patients with partly solid nodules. The study authors also pointed to a 73 percent 20-year survival rate in 991 people who had solid nodule presentations.2
“What we present here is the 20-year follow-up on participants in our screening program that were diagnosed with lung cancer and subsequently treated,” noted lead study author Claudia Henschke, Ph.D., M.D., a professor of radiology and director of the Early Lung and Cardiac Action Program at the Icahn School of Medicine at Mount Sinai in New York. “The key finding is that even after this long-time interval, they are not dying of their lung cancer.”
Henschke and colleagues also noted an 86 percent survival rate for people diagnosed with stage 1A lung cancers and a 92 percent survival rate for study participants who underwent resection of pathologic stage 1A tumors that were 10 cm or less in average diameter and width.2
“While screening doesn’t prevent cancers from occurring, it is an important tool in identifying lung cancers in their early stage when they can be surgically removed,” said Dr. Henschke.
All of the study participants were enrolled in the International Early Lung Cancer Action Program (I-ELCAP), a multinational program that emphasizes advance CT lung cancer screening and has enrolled over 87,000 people since 1992.
References
1. American Lung Association. New report: Critically low lung cancer screening rates reveal opportunity to save more lives. Available at: https://www.lung.org/media/press-releases/state-of-lung-cancer-2022 . Published November 15, 2022. Accessed November 21, 2022.
2. Radiological Society of North America (RSNA). Lung cancer screening dramatically increases long-term survival rate. Cision. PR Newswire. Available at: www.prnewswire.com/news-releases/lung-cancer-screening-dramatically-increases-long-term-survival-rate-301681836.html . Published November 22, 2022. Accessed November 22, 2022.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.